Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-220 dose-escalation study in relapsed or refractory multiple myeloma
NL-OMON54734Phase 2Recruiting
- Sponsor
- Celgene Corporation
- Start
- Jul 2017
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of iberdomide in multiple myeloma (MM) (10 cohorts), sponsored by Celgene Corporation. Primary endpoints: Recommended dose and regimen in Part 1 and Overall response rate in Cohort D. Started Jul 2017; status: recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON54734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54734.